Loading…
H.R. 6089119th CongressIn committeeLatest action Nov 18, 2025Decoded by AI · checked against the record
Official title: Biomanufacturing Excellence Act of 2025
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
HR 6089 would award up to $120M to build a NIST-run center improving U.S. biopharmaceutical manufacturing speed, cost, and supply independence.
60-second read · 5 questions answered below
HR 6089 would establish a National Biopharmaceutical Manufacturing Center of Excellence administered through the National Institute of Standards and Technology (NIST). The center would focus on improving how the United States manufactures biopharmaceuticals, including vaccines, insulin, and cancer treatments made from living cells or biological organisms. It would also help move new manufacturing methods from laboratory research to large-scale commercial production and share findings with federal agencies and the public.
Workers in biotechnology and pharmaceutical industries would be directly affected, as the bill includes funding for job training programs in those fields. American drug and biotech companies, particularly smaller ones working to scale up products, would have access to the center's shared research and facilities.
The bill is aimed at making the United States more self-sufficient in producing medicines and reducing reliance on foreign manufacturing for supplies and equipment. Bridging the gap between laboratory-stage innovation and large-scale commercial production is identified as one of the biggest current challenges for American biotech companies.
The federal government would award up to $120 million to a single qualifying organization, which could be a university, a public-private partnership, or a group of such entities working together.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the House Committee on Science, Space, and Technology.